For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Hydra Biosciences, Inc.

USPTO Granted Patents = 49

CIPO Patents = 1

EPO Patents = 16

Forward Citations = 162

Loading Chart...

Loading Chart...

45 inventors (with patents filed for the assignee):

Jayhong A Chong (24 out of 32 patents)

Magdalene M Moran (20 out of 27 patents)

Christopher Fanger (16 out of 29 patents)

4. Xiaoguang Zhen (12 out of 14 patents)

5. Bertrand Leo Chenard (12 out of 62 patents)

6. Randall James Gallaschun (10 out of 16 patents)

7. Xinyuan Edward Wu (8 out of 19 patents)

8. Amy Ripka (8 out of 28 patents)

9. Manfred Weigele (8 out of 18 patents)

10. Howard P Ng (8 out of 76 patents)

11. Glenn R Larsen (8 out of 30 patents)

12. Dennis John Underwood (7 out of 29 patents)

13. Josh Mandel-Brehm (5 out of 6 patents)

14. Spencer David Kimball (4 out of 29 patents)

15. Colleen McNamara (4 out of 4 patents)

Core Competencies:

Substituted Xanthines

TRPC5 Modulators

TRPC6 Inhibitors

Transient Receptor Potential Channels

Chemical Warfare Agent Treatments

Anxiety Treatments

Pain Management

TRPA1 Antagonists

Sperm Hypermotility Modulators

TRPV3 Function Modulation

Quinazoline Derivatives

Pyrimidine Derivatives

49 patents: Sort by Forward Citations

1. 12291532 - Substituted xanthines as modulators of TRPC5 activity (2025-05-06),

2. 11958854 - Substituted xanthines and methods of use thereof (2024-04-16),

3. RE49699 - Inhibitors of TRPC6 (2023-10-17),

4. 11485740 - Inhibitors of TRPC6 (2022-11-01),

5. 11208409 - Substituted xanthines and methods of use thereof (2021-12-28),

6. 11198696 - Substituted xanthines as inhibitors of transient receptor potential cation channel subfamily c, member 5 activity (2021-12-14),

7. 10800757 - Inhibitors of TRPC6 (2020-10-13),

8. 10399982 - Substituted xanthines and methods of use thereof (2019-09-03),

9. 10329292 - Substituted xanthine derivatives (2019-06-25),

10. 10221177 - Inhibiting the transient receptor potential A1 ion channel (2019-03-05),

11. 9980968 - Compounds and compositions for treating chemical warfare agent-induced injuries (2018-05-29),

12. 9969736 - Substituted xanthines and methods of use thereof (2018-05-15),

13. 9951073 - Compounds and compositions for treating chemical warfare agent-induced injuries (2018-04-24),

14. 9895356 - Methods and compositions for treating anxiety (2018-02-20),

15. 9815838 - Methods and compositions for treating pain (2017-11-14),

Hydra Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of small molecule drugs for the treatment of pain and other neurological disorders. With a focus on understanding ion channel and GPCR biology, Hydra Biosciences aims to create innovative treatments that improve patient outcomes and quality of life. Their dedication to scientific excellence and collaboration with leading research institutions enables them to advance groundbreaking therapies for unmet medical needs.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

49 Patents

#46 in Cambridge, MA

#394 in Massachusetts

#6,915 in US

#13,865 in the World

Cambridge, MA, United States of America

Hydra Biosciences, Inc.

Forward Citations = 162

45 inventors:

Jayhong A Chong (24 out of 32 patents)

Magdalene M Moran (20 out of 27 patents)

Christopher Fanger (16 out of 29 patents)

4. Xiaoguang Zhen (12 out of 14 patents)

5. Bertrand Leo Chenard (12 out of 62 patents)

Please report any incorrect information to support@idiyas.com

Loading…